Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sintilimab + carboplatin + pemetrexed or sintilimab + cisplatin + pemetrexed
- Development stage
- Unknown
- Lead developer
- Innovent Biologics Technology Limited (Shanghai R&D Center)
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of the anti-PD-1 monoclonal antibody sintilimab with either carboplatin or cisplatin (both platinum-based chemotherapies) and the antifolate agent pemetrexed. Sintilimab is an immune checkpoint inhibitor that blocks programmed cell death protein 1 (PD-1), thereby enhancing T-cell mediated antitumor responses. Carboplatin and cisplatin are DNA-damaging agents that induce apoptosis in rapidly dividing cells, while pemetrexed inhibits folate-dependent enzymes involved in nucleotide synthesis, disrupting DNA replication in cancer cells. This combination has been investigated as a first-line treatment for advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) without EGFR mutations or ALK rearrangements[2][3][4][5].
- Brand names
- TyvytAlimtaParaplatinPlatinol
- Other names
- sintilimab plus platinum and pemetrexedsintilimab plus chemotherapysintilimab combination therapy
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on sintilimab + carboplatin + pemetrexed or sintilimab + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sintilimab + carboplatin + pemetrexed or sintilimab + cisplatin + pemetrexed.